Q-omics provides the consensus-scored TRADD profile across patient tissues and cancer cell-line models. TRADD expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, TRADD is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TRADD protein abundance shows 33,603 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LGG, KIRC, and GBM as cancer lineages where TRADD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRADD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRADD survival associations across molecular data types. TRADD RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRADD RNA expression–survival associations across cancer types. High TRADD expression shows unfavorable associations in LGG and READ, but favorable associations in KIRP, UCEC, SARC and ESCA. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for TRADD RNA expression.
This table summarizes TRADD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRADD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRADD shows higher tumor expression in KIRC, HNSC, KIRP, LIHC, COAD and BLCA. The KIRC box plot shows higher TRADD RNA expression in tumor versus normal tissue (log2 FC = +1.596, t-test p < 0.001).
This table shows molecular features associated with TRADD in patient tissues and cancer cell lines. In patient samples, TRADD shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRADD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
